Navigation Links
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
Date:2/15/2013

MUMBAI, February 15, 2013 /PRNewswire/ --

Bharatbook.com is pleased to announce a new research report on Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors (http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html)

New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years. This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935)

Key Points Discussed in the Report

  • Drugs in the pipeline

PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

  • M&A in Kinase Inhibitors in the last 5 years
  • Related Milestones/catalysts in 2013-14
  • Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
  • Ongoing Clinical Trials of Companies Covered
  • Detailed reports on

SymBio pharma (4582, ¥488)

Curis (CRIS, $2.99)

Gilead (GILD, $40.36)

Pharmacyclics (PCYC, $69.28) -

Infinity pharma (INFI, $35.02)

Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=372901

Table of Contents

Executive Summary

Drugs in the Pipeline

Phosphoinositide 3-Kinases (PI3Ks) inhibitors

Scientific Rationale

Dual inhibitors

Bruton's Tyrosin Kinase (BTK) Inhibitors

Scientific Rationale

BTK inhibitors - Pipeline

M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium

Kinase Inhibitor: Select M&A / Deals

Upcoming Milestones Related in 2013-14

Combination Studies - PI3K, BTK + Rituxan/ Bendamustine

Idelalisib (GS-1101) - Clinical Data

Rigosertib - Clinical Data

Other PI3K or Dual Inhibitors - Clinical Data

Combination Studies of PI3K and BTK Inhibitors

Ongoing Trials of PI3K and BTK Compounds

Company Analysis

Curis (CRIS) -

Gilead -

Infinity Pharma

Pharmacyclics

SymBio

Get an overview of the report at or request for sample pages at -

http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html

For Complete range of Related Reports:

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Maria
Bharat Book Bureau
India: +91-22-27810772, 27810773
USA/Canada - 1-866-279-8368 (Toll free)
Skype - bharatbook
E-mail: maria@bharatbook.com
Website: http://www.bharatbook.com


'/>"/>
SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
3. Kinase Inhibitors: Global Markets -- Focus on the U.S.
4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... 21, 2017 , ... Lajollacooks4u welcomed the San Diego chapter of Les Dames ... of professional women with high achievement in the fields of food, fine beverage and ... Twelve members began with an olive oil tasting to whet their palettes and then ...
(Date:9/20/2017)... ... September 20, 2017 , ... The award-winning ... Services (Koch) to feature new innovations aimed at helping farmers solve the problem ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ...
(Date:9/20/2017)... ... 20, 2017 , ... Diversity focused business accelerator, The Refinery , announced ... to uncover the top technology-driven, women-led startups in Boston, MA, New Haven/Hamden, CT, and ... entrepreneurial events going on that week – in Boston, it will be part of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia ... Pathology , a provider of whole slide imaging solutions, are hosting a pre-conference ... workshop, entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):